Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force

被引:8
作者
Miskowiak, Kamilla W. [1 ,2 ,26 ]
Obel, Zacharias K. [1 ,2 ]
Guglielmo, Riccardo [3 ,4 ]
Bonnin, Caterina del Mar [5 ]
Bowie, Christopher R. [6 ]
Balanza-Martinez, Vicente [7 ]
Burdick, Katherine E. [8 ,9 ]
Carvalho, Andre F. [10 ]
Dols, Annemieke [11 ]
Douglas, Katie [12 ]
Gallagher, Peter [13 ]
Kessing, Lars V. [2 ,14 ]
Lafer, Beny [15 ]
Lewandowski, Kathryn E. [8 ,16 ]
Lopez-Jaramillo, Carlos [17 ]
Martinez-Aran, Anabel [5 ]
Mcintyre, Roger S. [18 ]
Porter, Richard J. [12 ]
Purdon, Scot E. [19 ]
Schaffer, Ayal [20 ]
Stokes, Paul R. A. [21 ]
Sumiyoshi, Tomiki [22 ]
Torres, Ivan J. [23 ]
Van Rheenen, Tamsyn E. [24 ,25 ]
Yatham, Lakshmi N. [23 ]
Young, Allan H. [21 ]
Vieta, Eduard [5 ]
Hasler, Gregor [3 ]
机构
[1] Univ Copenhagen, Neurocognit & Emot Affect Disorders NEAD Ctr, Dept Psychol, Mental Hlth Serv, Copenhagen, Denmark
[2] Copenhagen Univ Hosp, Copenhagen Affect Disorder Res Ctr CADIC, Psychiat Ctr Copenhagen, Copenhagen, Denmark
[3] Univ Fribourg, Psychiat Res Unit, Fribourg, Switzerland
[4] Univ Genoa, Sect Psychiat, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy
[5] Univ Barcelona, Hosp Clin, Clin Inst Neurosci, IDIBAPS,CIBERSAM, Barcelona, Spain
[6] Queens Univ, Dept Psychol, Kingston, ON, Canada
[7] Univ Valencia, Dept Med, Valencia, Spain
[8] Harvard Med Sch, Dept Psychiat, Boston, MA USA
[9] Brigham & Womens Hosp, Dept Psychiat, Boston, MA USA
[10] Deakin Univ, IMPACT Strateg Res Ctr Innovat Mental & Phys Hlth, Geelong, Vic, Australia
[11] Univ Med Ctr Utrecht, UMC Utrecht Brain Ctr, Dept Psychiat, Utrecht, Netherlands
[12] Univ Otago, Dept Psychol Med, Christchurch, New Zealand
[13] Newcastle Univ, Translat & Clin Res Inst, Fac Med Sci, Newcastle Upon Tyne, England
[14] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[15] Univ Sao Paulo, Hosp Clin, Inst Psychiat, Fac Med,Bipolar Disorder Res Program, Sao Paulo, Brazil
[16] McLean Hosp, Schizophrenia & Bipolar Disorder Program, Belmont, MA USA
[17] Univ Antioquia, Res Grp Psychiat, Dept Psychiat, Medellin, Colombia
[18] Univ Toronto, Brain & Cognit Discovery Fdn, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada
[19] Univ Alberta, Dept Psychiat, Edmonton, AB, Canada
[20] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[21] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London, England
[22] Natl Inst Mental Hlth, Natl Ctr Neurol & Psychiat, Dept Prevent Intervent Psychiat Disorders, Tokyo, Japan
[23] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada
[24] Univ Melbourne, Melbourne Neuropsychiat Ctr, Dept Psychiat, Carlton, Vic, Australia
[25] Swinburne Univ, Fac Hlth Arts & Design, Ctr Mental Hlth, Melbourne, Vic, Australia
[26] Frederiksberg Univ Hosp, NEAD Ctr, Psychiat Ctr Copenhagen, Mental Hlth Serv, Hovedvejen 17, DK-2000 Frederiksberg, Denmark
基金
欧洲研究理事会;
关键词
attention-deficit hyperactivity disorder; cognitive impairment; bipolar disorder; ISBD task force; medication; recommendations; systematic review; CATECHOL-O-METHYLTRANSFERASE; DOPAMINE TRANSPORTER GENE; DOUBLE-BLIND; ADJUNCTIVE ARMODAFINIL; DEFICIT/HYPERACTIVITY-DISORDER; SEQUENCE VARIATION; PREFRONTAL CORTEX; I DISORDER; BUPROPION; MODAFINIL;
D O I
10.1111/bdi.13414
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundAbnormalities in dopamine and norepinephrine signaling are implicated in cognitive impairments in bipolar disorder (BD) and attention-deficit hyperactivity disorder (ADHD). This systematic review by the ISBD Targeting Cognition Task Force therefore aimed to investigate the possible benefits on cognition and/or ADHD symptoms and safety of established and off-label ADHD therapies in BD.MethodsWe included studies of ADHD medications in BD patients, which involved cognitive and/or safety measures. We followed the procedures of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 statement. Searches were conducted on PubMed, Embase and PsycINFO from inception until June 2023. Two authors reviewed the studies independently using the Revised Cochrane Collaboration's Risk of Bias tool for Randomized trials.ResultsSeventeen studies were identified (N = 2136), investigating armodafinil (k = 4, N = 1581), methylphenidate (k = 4, N = 84), bupropion (k = 4, n = 249), clonidine (k = 1, n = 70), lisdexamphetamine (k = 1, n = 25), mixed amphetamine salts (k = 1, n = 30), or modafinil (k = 2, n = 97). Three studies investigated cognition, four ADHD symptoms, and 10 the safety. Three studies found treatment-related ADHD symptom reduction: two involved methylphenidate and one amphetamine salts. One study found a trend towards pro-cognitive effects of modafinil on some cognitive domains. No increased risk of (hypo)mania was observed. Five studies had low risk of bias, eleven a moderate risk, and one a serious risk of bias.ConclusionsMethylphenidate or mixed amphetamine salts may improve ADHD symptoms in BD. However, there is limited evidence regarding the effectiveness on cognition. The medications produced no increased mania risk when used alongside mood stabilizers. Further robust studies are needed to assess cognition in BD patients receiving psychostimulant treatment alongside mood stabilizers.
引用
收藏
页码:216 / 239
页数:24
相关论文
共 73 条
[31]   Attention-based classification pattern, a research domain criteria framework, in youths with bipolar disorder and attention-deficit/hyperactivity disorder [J].
Kleinman, Ana ;
Caetano, Sheila Cavalcante ;
Brentani, Helena ;
de Almeida Rocca, Cristiana Castanho ;
dos Santos, Bernardo ;
Andrade, Enio Roberto ;
Zeni, Cristian Patrick ;
Tramontina, Silza ;
Paim Rohde, Luis Augusto ;
Lafer, Beny .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2015, 49 (03) :255-265
[32]   Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents [J].
Kowalczyk, Olivia S. ;
Cubillo, Ana I. ;
Smith, Anna ;
Barrett, Nadia ;
Giampietro, Vincent ;
Brammer, Michael ;
Simmons, Andrew ;
Rubia, Katya .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 (10) :1102-1116
[33]   Combination pharmacotherapy in children and adolescents with bipolar disorder [J].
Kowatch, RA ;
Sethuraman, G ;
Hume, JH ;
Kromelis, M ;
Weinberg, WA .
BIOLOGICAL PSYCHIATRY, 2003, 53 (11) :978-984
[34]   Approved and investigational uses of modafinil - An evidence-based review [J].
Kumar, Raminder .
DRUGS, 2008, 68 (13) :1803-1839
[35]   Relation between therapeutic response and side effects induced by methylphenidate as observed by parents and teachers of children with ADHD [J].
Lee, James ;
Grizenko, Natalie ;
Bhat, Venkataramana ;
Sengupta, Sarojini ;
Polotskaia, Anna ;
Joober, Ridha .
BMC PSYCHIATRY, 2011, 11
[36]   Modafinil's effects on cognition and sleep quality in affectively-stable patients with bipolar disorder: a pilot study [J].
Lipschitz, Jessica M. ;
Perez-Rodriguez, Mercedes ;
Majd, Marzieh ;
Larsen, Emmett ;
Locascio, Joseph ;
Pike, Chelsea K. ;
Shanahan, Megan ;
Burdick, Katherine E. .
FRONTIERS IN PSYCHIATRY, 2023, 14
[37]   Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder [J].
Mazei-Robison, MS ;
Couch, RS ;
Shelton, RC ;
Stein, MA ;
Blakely, RD .
NEUROPHARMACOLOGY, 2005, 49 (06) :724-736
[38]   Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial [J].
McElroy, Susan L. ;
Martens, Brian E. ;
Mori, Nicole ;
Blom, Thomas J. ;
Casuto, Leah S. ;
Hawkins, John M. ;
Keck, Paul E., Jr. .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2015, 30 (01) :6-13
[39]   The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder [J].
McIntyre, Roger S. ;
Alsuwaidan, Mohammad ;
Soczynska, Joanna K. ;
Szpindel, Isaac ;
Bilkey, Timothy S. ;
Almagor, Doron ;
Woldeyohannes, Hanna O. ;
Powell, Alissa M. ;
Cha, Danielle S. ;
Gallaugher, Laura Ashley ;
Kennedy, Sidney H. .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2013, 28 (05) :421-427
[40]   Topiramate versus Bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study [J].
McIntyre, RS ;
Mancini, DA ;
McCann, S ;
Srinivasan, J ;
Sagman, D ;
Kennedy, SH .
BIPOLAR DISORDERS, 2002, 4 (03) :207-213